AKT1 and central nervous system cancer: Indeed, this concept was tested in one approach, which combined the lysosomotrophic agent chloroquine (CQ) that blocked the activity of lysosomal proteases, with the PI3K/mTOR/AKT inhibitors (AKT-1/2 and PI-103), resulting in the overall potentiation of glioma cell death [199].